Niagen Bioscience, Inc. (NASDAQ: NAGE) is a global bioscience company
advancing NAD+ science through its Niagen® platform, a patented NAD+
booster, protected by a 100+ patent estate.
Niagen® powers four distinct verticals: consumer health, telehealth and
injectables, ingredients, and rare disease therapeutics. The Company’s
successful flagship supplement brand Tru Niagen® and Niagen® Plus, its
IV/injectable products available across 1,700+ clinics and a
direct-to-patient telehealth network, are funding the pharmaceutical
development of its lead clinical asset, NB4168, initially targeting rare genetic disease Ataxia Telangiectasia.
Demand for Niagen’s portfolio of evidence-based longevity solutions
continues to increase as awareness of the benefits of NAD+ becomes
mainstream, supporting the Company’s consistent profitable growth since
2014.
NAD+ is an essential coenzyme present in all living cells and is fundamental
to mitochondrial bioenergetics, metabolic homeostasis, and genomic
stability. Research shows NAD+ levels decline with age and metabolic stress,
correlating with diminished cellular function and physiological resilience.
In 2025, Niagen delivered $129.4 million in net sales (+30% YoY) and 64.3%
gross margin (+250 bps YoY), with net income of $17.4 million (+103% YoY)
and $13.5 million in operating cash flow, ending the year with $64.8 million
in cash and no outstanding borrowings.